» Articles » PMID: 29158891

Overexpression of Hypoxia-inducible Factor and Metabolic Pathways: Possible Targets of Cancer

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2017 Nov 22
PMID 29158891
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer, the main cause of human deaths in the modern world is a group of diseases. Anticancer drug discovery is a challenge for scientists because of involvement of multiple survival pathways of cancer cells. An extensive study on the regulation of each step of these pathways may help find a potential cancer target. Up-regulated HIF-1 expression and altered metabolic pathways are two classical characteristics of cancer. Oxygen-dependent (through pVHL, PHDs, calcium-mediated) and independent (through growth factor signaling pathway, mdm2 pathway, HSP90) regulation of HIF-1α leads to angiogenesis, metastasis, and cell survival. The two subunits of HIF-1 regulates in the same fashion through different mechanisms. HIF-1α translation upregulates via mammalian target of rapamycin and mitogen-activated protein kinase signaling pathways, whereas HIF-1β through calmodulin kinase. Further, the stabilized interactions of these two subunits are important for proper functioning. Also, metabolic pathways crucial for the formation of building blocks (pentose phosphate pathway) and energy generation (glycolysis, TCA cycle and catabolism of glutamine) are altered in cancer cells to protect them from oxidative stress and to meet the reduced oxygen and nutrient supply. Up-regulated anaerobic metabolism occurs through enhanced expression of hexokinase, phosphofructokinase, triosephosphate isomerase, glucose 6-phosphate dehydrogenase and down-regulation of aerobic metabolism via pyruvate dehydrogenase kinase and lactate dehydrogenase which compensate energy requirements along with high glucose intake. Controlled expression of these two pathways through their common intermediate may serve as potent cancer target in future.

Citing Articles

Redefining the role of hypoxia-inducible factors (HIFs) in oxygen homeostasis.

Arias C, Acosta F, Bertocchini F, Fernandez-Arias C Commun Biol. 2025; 8(1):446.

PMID: 40089642 DOI: 10.1038/s42003-025-07896-1.


Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia.

Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).

PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.


HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects.

Shi Y, Gilkes D Cell Mol Life Sci. 2025; 82(1):44.

PMID: 39825916 PMC: 11741981. DOI: 10.1007/s00018-024-05537-0.


CircRNAs: A promising target for intervention regarding glycolysis in gastric cancer.

Dai Q, Liu Y, Ding F, Guo R, Cheng G, Wang H Heliyon. 2025; 10(14):e34658.

PMID: 39816354 PMC: 11734058. DOI: 10.1016/j.heliyon.2024.e34658.


Correlation between CT spectral quantitative parameters and expression levels of HIF-1α and ALX1 in non-small cell lung cancer.

Jia Y, Sun Q, Wang Y, Jiang H, Xiao X Medicine (Baltimore). 2024; 103(48):e40508.

PMID: 39612428 PMC: 11608659. DOI: 10.1097/MD.0000000000040508.


References
1.
Sun L, Burnett J, Gasparyan M, Xu F, Jiang H, Lin C . Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. Oncotarget. 2016; 7(32):51408-51422. PMC: 5239484. DOI: 10.18632/oncotarget.9839. View

2.
Giaccia A, Siim B, Johnson R . HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003; 2(10):803-11. DOI: 10.1038/nrd1199. View

3.
Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

4.
Warburg O . On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-70. View

5.
Onnis B, Rapisarda A, Melillo G . Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009; 13(9A):2780-6. PMC: 2832082. DOI: 10.1111/j.1582-4934.2009.00876.x. View